Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Deterding

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
The Journal of Infectious Diseases|September 10, 2016
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis BChristoph Höner Zu Siederdissen, Franziska Rinker, Benjamin Maasoumy, et al.
The Journal of Infectious Diseases|October 25, 2013
Compromised function of natural killer cells in acute and chronic viral hepatitisSebastian Lunemann, David F G Malone, Julia Hengst, et al.
Journal of Hepatology|April 18, 2016
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimensBenjamin Maasoumy, Johannes Vermehren, Martin-Walter Welker, et al.
Hepatology (Baltimore, Md.)|January 23, 2025
TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis DPo-Chun Chen, Katja Deterding, Sophie Anna Engelskircher, et al.
JHEP Reports : Innovation in Hepatology|February 28, 2023
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V studyBenjamin Maasoumy, Patrick Ingiliz, Christoph D Spinner, et al.
Journal of Hepatology|March 13, 2024
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis deltaMathias Jachs, Lisa Sandmann, Lukas Hartl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus PanelYestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2012
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcomeBenjamin Heidrich, Beatriz C Serrano, Ramazan Idilman, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
The Journal of Infectious Diseases|September 10, 2016
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis BChristoph Höner Zu Siederdissen, Franziska Rinker, Benjamin Maasoumy, et al.
The Journal of Infectious Diseases|October 25, 2013
Compromised function of natural killer cells in acute and chronic viral hepatitisSebastian Lunemann, David F G Malone, Julia Hengst, et al.
Journal of Hepatology|April 18, 2016
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimensBenjamin Maasoumy, Johannes Vermehren, Martin-Walter Welker, et al.
Hepatology (Baltimore, Md.)|January 23, 2025
TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis DPo-Chun Chen, Katja Deterding, Sophie Anna Engelskircher, et al.
JHEP Reports : Innovation in Hepatology|February 28, 2023
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V studyBenjamin Maasoumy, Patrick Ingiliz, Christoph D Spinner, et al.
Journal of Hepatology|March 13, 2024
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis deltaMathias Jachs, Lisa Sandmann, Lukas Hartl, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus PanelYestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Gut|April 12, 2012
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosisRoeland Zoutendijk, Jurrien G P Reijnders, Fabien Zoulim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2012
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcomeBenjamin Heidrich, Beatriz C Serrano, Ramazan Idilman, et al.
Pageof 10